U.S. Markets close in 20 mins

Integra LifeSciences FDA warning likely to be lifted in two months, says Argus

After the FDA reported that Integra had remedied issues previously identified by the agency at one of its plants, Argus expects the FDA to lift its warning letter related to the issues within two months. The firm expects the FDA's decision to pave the way for increased production of DuraGen, a regenerative medicine product used by neurosurgeons. Argus keeps a $50 price target and Buy rating on Integra.